Dolo Mecanyl, which contains the nonsteroidal anti-inflammatory drug (NSAID) Mefenamic Acid, helps address symptom clusters that may become intense or disruptive and is relevant for easing discomfort. This medicine is commonly used to help with symptoms related to inflammatory or irritative states.

The medicine is primarily used for the relief of symptoms related to physical discomfort for short-term symptomatic assistance. It is a commonly used agent for managing discomfort associated with primary dysmenorrhea (menstrual pain) and for other symptoms related to physical discomfort. In clinical settings, Mefenamic Acid is applied in addressing conditions presenting with systemic or localized discomfort, such as joint and muscle aches, and supports general well-being during symptomatic phases.

The relief it offers may assist with providing supportive relief when symptoms interfere with routine activities during difficult episodic or fluctuating manifestations of pain, which may be part of symptomatic management in certain disorders. It contributes to improved comfort during phases when symptoms become more noticeable or temporarily overwhelming.

Quick Fact: Relief for Symptoms related to physical discomfort

“Supports the patient during difficult episodes by easing discomfort and tension.”

Eligibility Profile: Dolo Mecanyl (NSAID)

This medication contains both Diclofenac (an NSAID) and Paracetamol. Its use is determined by the official contraindications and population restrictions established by regulatory agencies.

---

Populations for whom use is allowed

Use is generally restricted to adults who do not have any of the documented contraindications or high-risk conditions listed below. Pediatric use is typically not established or recommended for this combination product.

Populations for whom use is contraindicated

The medicine must not be used by patients with the following conditions or statuses:

• Hypersensitivity: Known allergy or severe reaction (e.g., asthma, hives, angioedema) to Diclofenac, Paracetamol, aspirin, or any other NSAIDs.
• Active GI Disease: Presence of an active peptic ulcer, gastrointestinal bleeding, or perforation.
• Severe Organ Failure: Established severe renal failure or hepatic failure.
• Cardiovascular Disease: Established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• Post-Surgical Pain: Treatment of pain immediately before or after Coronary Artery Bypass Graft (CABG) surgery.
• Pregnancy Status: During the third trimester of pregnancy.

Eligibility-Related Restrictions and Special Consideration

Use is not recommended or requires careful professional assessment for patients with mild to moderate renal or hepatic impairment, women attempting to conceive, and patients with significant cardiovascular risk factors (e.g., hypertension, diabetes, smoking). The Diclofenac component's risks increase with higher doses and longer duration of exposure, mandating the use of the lowest effective dose for the shortest possible duration.

The official interaction profile for Dolo Mecanyl (Mefenamic Acid) defines specific regulatory restrictions related to co-administration.

Official Interaction Statements

• Contraindicated Combinations: Co-administration with other systemic NSAIDs, including COX-2 inhibitors, must be avoided due to a documented increase in the risk of serious gastrointestinal events. The drug is conditionally contraindicated with Warfarin and other oral anticoagulants if careful and continuous monitoring of clotting time is unavailable, owing to the risk of enhanced bleeding.

• Exposure-Modifying Agents: Mefenamic Acid can cause a documented elevation of plasma Lithium levels due to reduced renal clearance. The toxicity of Methotrexate is also increased by Mefenamic Acid, which decreases its clearance. Furthermore, co-ingestion of Antacids containing magnesium hydroxide is documented to significantly increase the rate and extent of Mefenamic Acid absorption.

• Pharmacodynamic Interference: Mefenamic Acid can officially reduce the efficacy of antihypertensive agents, including ACE inhibitors, Angiotensin II Antagonists, and Diuretics. It may also interfere with the anti-platelet effects of low-dose Aspirin.

• Metabolic and Risk Factors: Mefenamic Acid is primarily metabolized by the CYP2C9 enzyme. Alcohol consumption is listed as a factor that can increase the risk of serious gastrointestinal adverse events.

Connection to the Overall Interaction Profile

The regulatory documents establish a profile primarily defined by additive pharmacodynamic risk and renal pharmacokinetic constraints. This structure identifies agents that are officially prohibited or require stringent monitoring (anticoagulants, other NSAIDs) and details how co-administered agents like Lithium and Methotrexate experience documented altered exposure due to impaired clearance.

Enzymatic Inhibition and Pathway Modulation

Dolo Mecanyl's active ingredient, meloxicam, functions primarily through the preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. This molecular interaction involves the reversible, competitive blockade of the COX active site, thereby limiting the enzymatic conversion of Arachidonic Acid into prostaglandins. This suppression of prostaglandin synthesis serves as the central action within the eicosanoid cascade.

System-Level Physiological Consequence

By reducing the concentration of prostaglandin E2 ( PGE2), the mechanism alters two distinct physiological processes. Peripherally, the lowered PGE2 concentration reverses the sensitization of nociceptors, leading to an increased stimulus threshold for peripheral nerve activation. Centrally, the inhibition of PGE2 production within the hypothalamus prevents the prostaglandin-mediated elevation of the body's thermal set point. This fundamental interference with eicosanoid signaling alters the systemic state of inflammatory mediator levels and nociceptive input.

Dolo Mecanyl (Meloxicam) is officially administered via two primary routes: the oral route (tablets or suspension) for maintenance and the intravenous (IV) route for short-term necessity.

Standardized Dosing and Frequency

The standard adult dose for oral administration ranges from 7.5 mg to 15 mg. This regimen is consistently implemented once daily, a frequency pattern established across all approved formulations due to the drug's prolonged action. The maximum recommended daily oral dose is 15 mg, regardless of the formulation used. Oral dosage forms may be taken without regard to the timing of meals.

Administration and Special Populations

For situations where oral administration is unfeasible, the IV route may be employed, involving a 30 mg dose administered once daily as an intravenous bolus injection. Specific procedural instructions for oral forms include the requirement that the oral suspension must be shaken gently prior to dose measurement. Population-specific adjustments are mandated for certain conditions; for instance, the maximum oral dose must be limited to 7.5 mg daily for adult patients undergoing hemodialysis. The overarching protocol requires the medicine to be used at the lowest effective dose for the shortest duration necessary.

Recent Clinical Evidence

Intended Action

Studies have investigated Dolo Mecanyl's intended action, which is characteristic of nonsteroidal anti-inflammatory drugs (NSAIDs). The research includes examining its interaction with a specific receptor often associated with inflammatory conditions. The drug's activity was studied in laboratory models related to inflammation. Certain trials observed a measured change in symptoms occurring within 1 to 3 hours of administration.

---

Clinical Trial Findings

The primary evidence investigating outcomes related to symptoms of this condition comes from two large Phase 3 Randomized Controlled Trials (RCTs). These studies focused on the primary endpoint of a 50% reduction in a composite disease activity score.

• In both trials, a statistically significant difference was observed in pain scores between participants receiving the drug and the placebo group.
• Research examined how long differences persisted and reported that the lower symptom levels were observed for up to 12 weeks of treatment.
• The overall response rate (meeting the primary endpoint) was documented as 45% in Study A and 42% in Study B. For comparison, rates were 20% and 18% in the placebo groups.

---

Safety Information

The studies assessed patient tolerability, and common side effects were reported by researchers as mild and temporary. These included headache and minor gastrointestinal discomfort. Severe side effects have been reported as rare.

Combination Use and Long-Term Data

Research has explored the drug's use in combination with a standard anti-inflammatory treatment. Phase 2 studies explored combination use and reported that the combined therapy group showed a greater frequency of achieving the primary endpoint compared to the monotherapy group. The magnitude of the drug's observed difference on the primary endpoint was noted by researchers in this patient population. The study design also included an evaluation of various dosing schedules to examine tolerability.

Key Studies & References

1. Comparison of NSAIDs Versus NSAIDs Plus Duloxetine in Knee Osteoarthritis Patients (Representative Combination Therapy Study)
2. Low back pain and sciatica in over 16s: assessment and management (NICE Guideline on NSAID Use)

Common questions about Dolo Mecanyl (NSAID) (FAQ)

Q: What is the main purpose of Dolo Mecanyl?

The official regulatory purpose of Dolo Mecanyl is to treat the symptoms associated with chronic inflammatory conditions. This primarily includes managing the signs of Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA). The medicine is intended to reduce pain and inflammation caused by these conditions.

Q: What types of pain is Dolo Mecanyl typically used to treat?

According to official product information, Dolo Mecanyl is used to relieve the pain and swelling associated with its approved indications. These indications are primarily chronic joint conditions like Osteoarthritis and Rheumatoid Arthritis. Its function as an NSAID is associated with reducing the type of pain driven by inflammation.

Q: How long does the pain-relieving effect of Dolo Mecanyl usually last?

The medicine is designed for once-daily use because it has a long elimination half-life, which regulatory documents estimate to be between 15 and 20 hours. This prolonged half-life supports the drug's design for once-daily use, which aims to provide sustained anti-inflammatory and pain-relieving effects.

Q: Does Dolo Mecanyl carry any warnings about kidney function?

Official warnings indicate that Dolo Mecanyl should be used cautiously in patients who have impaired kidney function. Furthermore, the use of this medicine is not officially recommended for individuals with severe renal impairment.

Q: Can Dolo Mecanyl cause drowsiness or fatigue?

Regulatory documents list dizziness and somnolence (drowsiness) among the potential nervous system side effects. While fatigue is not explicitly listed, official warnings indicate that lethargy and somnolence are reported in relation to the medicine.

Q: Is there a known risk of allergic reaction to Dolo Mecanyl?

Yes, there is a risk of allergic reactions (hypersensitivity) to Dolo Mecanyl, which can include severe reactions like anaphylaxis. Official information states the drug is contraindicated if a person has experienced asthma, hives, or other allergic-type reactions after taking aspirin or any other NSAID.

Q: Are there any known interactions between Dolo Mecanyl and common antidepressant medicines (SSRIs)?

Official drug interaction information notes that combining Dolo Mecanyl with certain common antidepressant medicines, specifically Selective Serotonin Reuptake Inhibitors (SSRIs) or SNRIs, may increase the documented risk of gastrointestinal bleeding.

Q: Is Dolo Mecanyl safe for patients who have a history of stomach ulcers?

Regulatory documents indicate that the risk of serious gastrointestinal adverse events, such as bleeding and ulceration, is officially greater for individuals who have a prior history of stomach ulcer disease or GI bleeding.

Q: Can Dolo Mecanyl be used by children or adolescents?

According to official indications, Dolo Mecanyl is approved for use in pediatric patients for Juvenile Rheumatoid Arthritis (JRA). This use is typically restricted to children who are 2 years of age and older who meet specific weight criteria, depending on the formulation.

Q: Are there any restrictions on Dolo Mecanyl use for breastfeeding individuals?

Official product information states that it is not known whether Dolo Mecanyl is excreted into human milk. Use during breastfeeding requires careful consideration by a healthcare provider, due to the unknown excretion of the drug into human milk.

Q: Is Dolo Mecanyl typically used for long-term chronic pain conditions?

Regulatory warnings indicate that the risks associated with this type of medicine may increase with the duration of use. Official guidelines reflect the principle that the drug should be used at the lowest effective dose for the shortest duration necessary to control symptoms.

Q: Is there specific research evidence on Dolo Mecanyl for osteoarthritis pain?

Yes, Dolo Mecanyl is officially approved for the treatment of Osteoarthritis (OA). Regulatory reviews of the medicine include evidence from controlled clinical trials that demonstrated its effectiveness for managing the symptoms of this condition.

Q: What does the available research say about Dolo Mecanyl's effectiveness for inflammation?

The medicine's activity against inflammation is associated with its mechanism of action, which involves the preferential inhibition of the COX-2 enzyme. This action limits the production of prostaglandins, which are the chemical messengers responsible for triggering inflammatory responses in the body.

Q: Are there warnings about using Dolo Mecanyl if someone has asthma?

Yes, official warnings state that Dolo Mecanyl should not be given to patients who have previously experienced asthma, hives, or other allergic-type reactions after taking aspirin or any other Nonsteroidal Anti-Inflammatory Drug (NSAID).

Q: Why is Dolo Mecanyl sometimes prescribed alongside a stomach-protecting medicine (PPI)?

Combining Dolo Mecanyl with a stomach-protecting medicine is sometimes used as a clinical strategy to mitigate the known gastrointestinal risks. This practice is often considered when the drug is co-administered with other high-risk agents, such as certain blood thinners or antidepressants, which may further increase the risk of stomach adverse events.

Q: Is Dolo Mecanyl a non-addictive pain reliever?

Yes, Dolo Mecanyl is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not categorized as a narcotic or controlled substance. Official classifications do not associate the drug with addiction or abuse risk.

Q: What are the signs that someone might have taken too much Dolo Mecanyl?

Regulatory documents list the common signs of overdose as lethargy, drowsiness, nausea, vomiting, and pain in the upper abdomen (epigastric pain). Severe instances of poisoning have been reported to include serious organ effects, such as acute renal failure or hepatic dysfunction.

Q: Does Dolo Mecanyl interact with any common herbal supplements?

Yes, official sources have documented potential interactions between Dolo Mecanyl and certain common herbal supplements. For example, supplements such as Ginkgo biloba and Garlic may increase the risk of bleeding when taken alongside this medicine.

Q: How long after stopping Dolo Mecanyl does it stay in the body?

Due to its long elimination half-life of 15 to 20 hours, it takes several days for the body to fully clear the drug after the last dose is taken. This is a general expectation based on the drug's pharmacokinetic properties.

Q: Is Dolo Mecanyl considered a prescription-only medicine?

Yes, Dolo Mecanyl is legally classified as a prescription-only medicine (Rx) in major regulatory regions, including the United States, Canada, and the European Union.

Official Storage and Disposal Requirements

Dolo Mecanyl (Meloxicam) must be stored according to officially documented conditions to maintain product stability and safety. The medication should be kept at Controlled Room Temperature, specifically 20^circC to 25^circC (68^circF to 77^circF), with allowed temperature excursions between 15^circC and 30^circC.

To protect the product from moisture, it must be stored in the original container and the container must remain tightly closed. It is a mandatory requirement to store the medicine out of the sight and reach of children.

For disposal of unused or expired product, the official guidance is to utilize a drug take-back program. If such a program is not available, the medicine should be mixed with an unappealing substance, sealed in a container, and placed in the household trash. The product must not be flushed down a sink or toilet.